As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.
8 Analysts have issued a Adagio Therapeutics Inc forecast:
8 Analysts have issued a Adagio Therapeutics Inc forecast:
Jun '25 |
+/-
%
|
||
Revenue | 46 46 |
1,945%
1,945%
|
|
Gross Profit | 43 43 |
1,880%
1,880%
|
|
EBITDA | -110 -110 |
49%
49%
|
|
EBIT (Operating Income) EBIT | -114 -114 |
47%
47%
|
|
Net Profit | -110 -110 |
46%
46%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren? Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.
Head office | United States |
CEO | William Duke |
Employees | 100 |
Founded | 2020 |
Website | invivyd.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.